Category: Latest News
-

Nexstar shares drop after judge orders pause in Tegna merger
Shares of Nexstar Media Group (NASDAQ:NXST) fell about 9% on Monday after a federal judge ordered the broadcaster to halt further integration efforts tied to its recently completed merger with Tegna Inc. U.S. District Judge Troy L. Nunley in Sacramento granted a request from DirecTV to temporarily stop the deal while litigation over the merger…
-

Insmed shares rise after UTHR trial data and Morgan Stanley upgrade
Insmed (NASDAQ:INSM) shares climbed about 4.7% on Monday after analysts reacted to positive clinical data from United Therapeutics and Morgan Stanley upgraded the stock to Overweight from Equalweight. Morgan Stanley also raised its price target on Insmed to $212 from $166 after conducting proprietary survey research on the launch of Brinsupri for bronchiectasis. The firm’s…
-

YY Group shares gain after company suspends ATM stock offering
YY Group Holding Ltd (NASDAQ:YYGH) shares climbed about 4.4% on Monday after the company announced it is suspending its At-The-Market (ATM) equity offering program and canceling more than 1 million shares that had not yet been issued. The workforce solutions and facilities management company said it instructed its sales agents, Spartan Capital Securities and Wilson-Davis…
-

Rezolve AI stock jumps after Q4 results highlight strong ARR growth
Rezolve AI Ltd (NASDAQ:RZLV) shares surged in premarket trading after the company reported its fourth-quarter and full-year 2025 results, highlighting strong growth in annual recurring revenue and improving operating performance. The stock climbed about 19% before the open to around $2.85 following the earnings release, as investors reacted positively to the company’s growth outlook despite…
-

Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors
Guardant Health, Inc. (NASDAQ:GH) said real-world evidence generated through its InfinityAI platform helped support the recent approval of ENHERTU® (trastuzumab deruxtecan) in Japan for patients with previously treated HER2-positive metastatic solid tumors. Japan’s Ministry of Health, Labour and Welfare (MHLW) granted the approval for ENHERTU, which is developed and commercialized by Daiichi Sankyo (TSE:4568), for…
-

Jeffs’ Brands rebrands as Nexera Technologies, adopts new Nasdaq ticker
Jeffs’ Brands Ltd (NASDAQ:JFBR) announced that it has changed its corporate name to Nexera Technologies Ltd, effective March 26, 2026, reflecting a strategic shift toward advanced technology and homeland security solutions. Beginning March 31, 2026, the company’s shares will trade on the Nasdaq Capital Market under the new ticker symbol “NEXR,” while its warrants will…
-

Quince Therapeutics settles $16.4M debt with $5.5M payment
Quince Therapeutics Inc. (NASDAQ:QNCX) announced that it has resolved its outstanding debt with the European Investment Bank through a settlement payment of $5.5 million, according to a company press release. The payment clears approximately $16.4 million in debt obligations as of March 27, 2026. With the settlement completed, both the agreement and the original loan…
-

PMGC Holdings reports 43% increase in assets, completes three acquisitions
PMGC Holdings Inc. (NASDAQ:ELAB) filed its fiscal 2025 annual report on Monday, reporting that total assets grew 43% year-over-year to about $12.87 million, up from $8.99 million in 2024, according to a company press release. The company currently has a market capitalization of roughly $0.9 million and a Price-to-Book ratio of 0.28, placing it among…
-

Sigma Lithium increases cash flow, reduces debt and signs $146 million in lithium offtake agreements
Sigma Lithium (NASDAQ:SGML) reported strong financial performance for 2025, posting $31 million in operating cash flow during the fourth quarter and achieving an operating cash margin of 47% as the company significantly lowered operating costs. The lithium producer also used a substantial portion of this cash to reduce its liabilities, finishing 2025 with total debt…
-

BullFrog AI signs commercial agreement with top global pharmaceutical company to identify drug targets for depression
BullFrog AI Holdings, Inc. (NASDAQ:BFRG), a technology company focused on applying artificial intelligence and machine learning to biomedical data analysis, announced a commercial agreement with one of the world’s top five pharmaceutical companies by revenue in 2025. The partnership will use BullFrog AI’s proprietary bfLEAP® platform to identify and prioritize potential therapeutic targets for major…